Cargando…
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
BACKGROUND: The addition of neutrophil-to-lymphocyte ratio (NLR) and bone metastases to the International Metastatic RCC Database Consortium (IMDC) score (by the Meet-URO score) has been shown to better stratify pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab. This stu...
Autores principales: | Rebuzzi, Sara Elena, Cerbone, Luigi, Signori, Alessio, Santoni, Matteo, Murianni, Veronica, De Giorgi, Ugo, Procopio, Giuseppe, Porta, Camillo, Milella, Michele, Basso, Umberto, Massari, Francesco, Maruzzo, Marco, Iacovelli, Roberto, Battelli, Nicola, Carmisciano, Luca, Banna, Giuseppe Luigi, Buti, Sebastiano, Fornarini, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883304/ https://www.ncbi.nlm.nih.gov/pubmed/35237353 http://dx.doi.org/10.1177/17588359221079580 |
Ejemplares similares
-
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2023) -
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
por: Rebuzzi, S.E., et al.
Publicado: (2022) -
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022) -
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022) -
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
por: Roviello, Giandomenico, et al.
Publicado: (2022)